Skip to main content
TipRanks
Go Ultimate75% OFF

Haw Par (H02) AI Stock Analysis

40 Followers
SG:H02

Haw Par

(SGX:H02)

Select Model
Rating:73Outperform
Price Target:SGD 14.50â–²(17.31% Upside)
Action:reiterated
Date:11/06/26

The overall score of 73 reflects a company with exceptional financial strength and an attractive valuation, weighed down by a weak technical trend. The primary driver is the robust balance sheet and surging cash flows, which provide a strong margin of safety. The low P/E and solid dividend yield further support the case. However, the stock is in a clear downtrend, trading below all major moving averages, which presents a significant headwind and tempers the overall score.

Positive Factors
Very low leverageThe exceptionally low debt burden gives Haw Par substantial financial flexibility and reduces exposure to interest costs and refinancing pressure. This conservative funding structure can help the company withstand operating volatility while preserving capacity to support healthcare growth, leisure operations, or investments.
Negative Factors
2025 revenue contractionThe reversal from several years of revenue expansion to a 2025 decline signals a meaningful slowdown in top-line momentum. Continued contraction would reduce operating leverage, constrain reinvestment in the healthcare franchise, and make it harder for the company to compound earnings over the next several quarters.

Haw Par (H02) vs. iShares MSCI Singapore ETF (EWS)

-20%-10%0%10%20%30%SG:H02-17.70%EWS+7.76%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SGD 2.18B
Dividend Yield
3.24%
Average Volume (3M)
267.84K
Price to Earnings (P/E)
11.9
Beta (1Y)
0.68
Revenue Growth
-13.24%
EPS Growth
-8.48%
Country
Singapore
Employees
595
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Haw Par Business Overview & Revenue Model

Company Description

Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business...

How the Company Makes Money

Haw Par makes money mainly through (1) consumer healthcare product sales and (2) income from its leisure/attractions activities, with additional contributions from (3) returns on its investment holdings. 1) Consumer healthcare (core operating revenue...

Haw Par Financial Statement Overview

Summary

Haw Par's financial health is excellent. The balance sheet is rock-solid with a 0.01 debt-to-equity ratio, and cash flow generation surged dramatically with a near 100% free cash flow conversion. Profitability is high, supported by a 56% gross margin, though the recent 9.1% revenue decline and reliance on investment income are minor concerns.

Income Statement

85Very Positive

Balance Sheet

90Very Positive

Cash Flow

95Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue219.55M229.97M244.82M232.06M182.09M141.18M
Gross Profit121.94M128.76M134.09M134.89M98.57M73.64M
EBITDA73.32M73.45M250.11M233.49M49.06M119.45M
Net Income229.19M265.46M228.27M216.57M148.32M110.10M
Balance Sheet
Total Assets4.88B4.42B4.28B3.59B3.65B3.28B
Cash, Cash Equivalents and Short-Term Investments881.34M834.71M3.93B3.21B3.18B596.23M
Total Debt52.60M44.27M36.30M28.48M58.40M1.52M
Total Liabilities133.88M126.83M128.47M117.17M101.41M72.08M
Stockholders Equity4.74B4.29B4.15B3.48B3.55B3.21B
Cash Flow
Free Cash Flow224.94M269.17M50.33M54.92M21.21M14.46M
Operating Cash Flow227.34M271.29M53.79M62.68M40.94M18.84M
Investing Cash Flow-187.29M76.93M199.82M258.00M-261.58M87.52M
Financing Cash Flow-70.80M-300.68M-82.79M-79.30M-38.07M-65.11M

Haw Par Technical Analysis

Technical Analysis SentimentNegative
Last Price12.36

Price Trends

50DMA13.02Negative
100DMA14.29Negative
200DMA15.23Negative

Market Momentum

MACD-0.17Positive
RSI33.16Neutral
STOCH10.31Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:H02, the sentiment is Negative. The current price of 12.36 is below the 20-day moving average (MA) of 12.77, below the 50-day MA of 13.02, and below the 200-day MA of 15.23, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 33.16 is Neutral, neither overbought nor oversold. The STOCH value of 10.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:H02.

Haw Par Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SG:H02 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SG:H02SG:H0273OutperformSGD 2.74B11.885.07%3.24%-13.24%-8.48%
SG:BSLSG:BSL63NeutralSGD 1.58B22.956.42%3.57%-3.18%6.71%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SG:A50SG:A5048NeutralSGD 1.19B-38.56-6.42%―6.44%38.89%

* Healthcare Sector Average

Performance Comparison

-20%-10%0%10%20%SG:H02SG:BSLSG:A50SG:1J5SG:40TSG:546Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SG:H02 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SG:H02Haw Par Corporation 12.36-2.45-16.51%
SG:BSLRaffles Medical Group 0.84-0.10-11.11%
SG:A50Thomson Medical Group Ltd.0.04-0.01-22.41%
SG:1J5Hyphens Pharma International Ltd.0.350.026.06%
SG:40TISEC Healthcare Ltd0.31-0.02-5.78%
SG:546Medtecs International Corporation Ltd.0.10-0.03-22.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026